<?xml version='1.0' encoding='utf-8'?>
<document id="8728350"><sentence text="Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine."><entity charOffset="11-23" id="DDI-PubMed.8728350.s1.e0" text="atorvastatin" /><entity charOffset="92-102" id="DDI-PubMed.8728350.s1.e1" text="antipyrine" /><pair ddi="false" e1="DDI-PubMed.8728350.s1.e0" e2="DDI-PubMed.8728350.s1.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s1.e0" e2="DDI-PubMed.8728350.s1.e1" /></sentence><sentence text="Possible effects of multiple-dose administration of atorvastatin on the pharmacokinetics of single-dose antipyrine were evaluated in this drug-drug interaction study"><entity charOffset="52-64" id="DDI-PubMed.8728350.s2.e0" text="atorvastatin" /><entity charOffset="104-114" id="DDI-PubMed.8728350.s2.e1" text="antipyrine" /><pair ddi="false" e1="DDI-PubMed.8728350.s2.e0" e2="DDI-PubMed.8728350.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s2.e0" e2="DDI-PubMed.8728350.s2.e1" /></sentence><sentence text=" Twelve healthy male volunteers received three 200-mg capsules of antipyrine on days 1 and 22, and two 40-mg atorvastatin tablets in the morning on days 8 through 23"><entity charOffset="66-76" id="DDI-PubMed.8728350.s3.e0" text="antipyrine" /><entity charOffset="109-121" id="DDI-PubMed.8728350.s3.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.8728350.s3.e0" e2="DDI-PubMed.8728350.s3.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s3.e0" e2="DDI-PubMed.8728350.s3.e1" /></sentence><sentence text=" Serial blood and urine samples were collected after administration of each antipyrine dose"><entity charOffset="76-86" id="DDI-PubMed.8728350.s4.e0" text="antipyrine" /></sentence><sentence text=" Plasma was analyzed for antipyrine, and urine samples were analyzed for antipyrine, 4-hydroxyantipyrine, and norantipyrine by validated high-performance liquid chromatography with ultraviolet detection"><entity charOffset="25-35" id="DDI-PubMed.8728350.s5.e0" text="antipyrine" /><entity charOffset="73-83" id="DDI-PubMed.8728350.s5.e1" text="antipyrine" /><entity charOffset="85-104" id="DDI-PubMed.8728350.s5.e2" text="4-hydroxyantipyrine" /><entity charOffset="110-123" id="DDI-PubMed.8728350.s5.e3" text="norantipyrine" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e0" e2="DDI-PubMed.8728350.s5.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e0" e2="DDI-PubMed.8728350.s5.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e0" e2="DDI-PubMed.8728350.s5.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e0" e2="DDI-PubMed.8728350.s5.e3" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e1" e2="DDI-PubMed.8728350.s5.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e1" e2="DDI-PubMed.8728350.s5.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e1" e2="DDI-PubMed.8728350.s5.e3" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e2" e2="DDI-PubMed.8728350.s5.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s5.e2" e2="DDI-PubMed.8728350.s5.e3" /></sentence><sentence text=" Overall, antipyrine and atorvastatin doses were well tolerated in healthy volunteers"><entity charOffset="10-20" id="DDI-PubMed.8728350.s6.e0" text="antipyrine" /><entity charOffset="25-37" id="DDI-PubMed.8728350.s6.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.8728350.s6.e0" e2="DDI-PubMed.8728350.s6.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s6.e0" e2="DDI-PubMed.8728350.s6.e1" /></sentence><sentence text=" Mean antipyrine concentrations in plasma after administration of a single, oral dose of antipyrine during coadministration of multiple doses of atorvastatin were nearly superimposible on concentrations after administration of antipyrine alone"><entity charOffset="6-16" id="DDI-PubMed.8728350.s7.e0" text="antipyrine" /><entity charOffset="89-99" id="DDI-PubMed.8728350.s7.e1" text="antipyrine" /><entity charOffset="145-157" id="DDI-PubMed.8728350.s7.e2" text="atorvastatin" /><entity charOffset="227-237" id="DDI-PubMed.8728350.s7.e3" text="antipyrine" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e0" e2="DDI-PubMed.8728350.s7.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e0" e2="DDI-PubMed.8728350.s7.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e0" e2="DDI-PubMed.8728350.s7.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e0" e2="DDI-PubMed.8728350.s7.e3" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e1" e2="DDI-PubMed.8728350.s7.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e1" e2="DDI-PubMed.8728350.s7.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e1" e2="DDI-PubMed.8728350.s7.e3" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e2" e2="DDI-PubMed.8728350.s7.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s7.e2" e2="DDI-PubMed.8728350.s7.e3" /></sentence><sentence text=" Individual and mean parameter values for plasma pharmacokinetics of antipyrine were similar in both treatment periods"><entity charOffset="69-79" id="DDI-PubMed.8728350.s8.e0" text="antipyrine" /></sentence><sentence text=" Atorvastatin did not significantly alter the fraction of clearance of antipyrine in plasma that occurred by urinary excretion of 4-hydroxyantipyrine and norantipyrine"><entity charOffset="1-13" id="DDI-PubMed.8728350.s9.e0" text="Atorvastatin" /><entity charOffset="71-81" id="DDI-PubMed.8728350.s9.e1" text="antipyrine" /><entity charOffset="130-149" id="DDI-PubMed.8728350.s9.e2" text="4-hydroxyantipyrine" /><entity charOffset="154-167" id="DDI-PubMed.8728350.s9.e3" text="norantipyrine" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e0" e2="DDI-PubMed.8728350.s9.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e0" e2="DDI-PubMed.8728350.s9.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e0" e2="DDI-PubMed.8728350.s9.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e0" e2="DDI-PubMed.8728350.s9.e3" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e1" e2="DDI-PubMed.8728350.s9.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e1" e2="DDI-PubMed.8728350.s9.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e1" e2="DDI-PubMed.8728350.s9.e3" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e2" e2="DDI-PubMed.8728350.s9.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s9.e2" e2="DDI-PubMed.8728350.s9.e3" /></sentence><sentence text=" These results indicate that the recommended highest daily dose of atorvastatin has negligible effects on antipyrine pharmacokinetics and on oxidative pathways responsible for the metabolism of antipyrine"><entity charOffset="67-79" id="DDI-PubMed.8728350.s10.e0" text="atorvastatin" /><entity charOffset="106-116" id="DDI-PubMed.8728350.s10.e1" text="antipyrine" /><entity charOffset="194-204" id="DDI-PubMed.8728350.s10.e2" text="antipyrine" /><pair ddi="false" e1="DDI-PubMed.8728350.s10.e0" e2="DDI-PubMed.8728350.s10.e0" /><pair ddi="false" e1="DDI-PubMed.8728350.s10.e0" e2="DDI-PubMed.8728350.s10.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s10.e0" e2="DDI-PubMed.8728350.s10.e2" /><pair ddi="false" e1="DDI-PubMed.8728350.s10.e1" e2="DDI-PubMed.8728350.s10.e1" /><pair ddi="false" e1="DDI-PubMed.8728350.s10.e1" e2="DDI-PubMed.8728350.s10.e2" /></sentence><sentence text="" /></document>